|
1
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group, :
Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 3 Suppl 25:iii27–iii39. 2014. View Article : Google Scholar
|
|
2
|
George RE, Sanda T, Hanna M, Fröhling S,
Luther W II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al:
Activating mutations in ALK provide a therapeutic target in
neuroblastoma. Nature. 455:975–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mossé YP, Laudenslager M, Longo L, Cole
KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P,
et al: Identification of ALK as a major familial neuroblastoma
predisposition gene. Nature. 455:930–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
George RE, Li S, Medeiros-Nancarrow C,
Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA and
Diller L: High-risk neuroblastoma treated with tandem autologous
peripheral-blood stem cell-supported transplantation: Long-term
survival update. J Clin Oncol. 24:2891–2896. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schwab M, Varmus HE, Bishop JM, Grzeschik
KH, Naylor SL, Sakaguchi AY, Brodeur G and Trent J: Chromosome
localization in normal human cells and neuroblastomas of a gene
related to c-myc. Nature. 308:288–291. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cole MD and Cowling VH:
Transcription-independent functions of MYC: Regulation of
translation and DNA replication. Nat Rev Mol Cell Biol. 9:810–815.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Slack A, Chen Z, Tonelli R, Pule M, Hunt
L, Pession A and Shohet JM: The p53 regulatory gene MDM2 is a
direct transcriptional target of MYCN in neuroblastoma. Proc Natl
Acad Sci USA. 102:pp. 731–736. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meyer N, Kim SS and Penn LZ: The
Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol.
16:275–287. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Molenaar JJ, Ebus ME, Geerts D, Koster J,
Lamers F, Valentijn LJ, Westerhout EM, Versteeg R and Caron HN:
Inactivation of CDK2 is synthetically lethal to MYCN
over-expressing cancer cells. Proc Natl Acad Sci USA. 106:pp.
12968–12973. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Malumbres M and Barbacid M: Mammalian
cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shapiro GI: Cyclin-dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hall C, Nelson DM, Ye X, Baker K, DeCaprio
JA, Seeholzer S, Lipinski M and Adams PD: HIRA, the human homologue
of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose
expression blocks S-phase progression. Mol Cell Biol. 21:1854–1865.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Futschik ME and Carlisle B: Noise-robust
soft clustering of gene expression time-course data. J Bioinform
Comput Biol. 3:965–988. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar L and Futschik E M: Mfuzz: A
software package for soft clustering of microarray data.
Bioinformation. 2:5–7. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
von Mering C, Huynen M, Jaeggi D, Schmidt
S, Bork P and Snel B: STRING: A database of predicted functional
associations between proteins. Nucleic Acids Res. 31:258–261. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao M, Sun J and Zhao Z: TSGene: A web
resource for tumor suppressor genes. Nucleic Acids Res. 41(Database
Issue): D970–D976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen JS, Hung WS, Chan HH, Tsai SJ and Sun
HS: In silico identification of oncogenic potential of fyn-related
kinase in hepatocellular carcinoma. Bioinformatics. 29:420–427.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Slack A and Shohet JM: MDM2 as a critical
effector of the MYCN oncogene in tumorigenesis. Cell Cycle.
4:857–860. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Slack AD, Chen Z, Ludwig AD, Hicks J and
Shohet JM: MYCN-directed centrosome amplification requires
MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Cancer Res. 67:2448–2455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vassilev LT, Vu BT, Graves B, Carvajal D,
Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et
al: In vivo activation of the p53 pathway by small-molecule
antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meek DW and Knippschild U:
Posttranslational modification of MDM2. Mol Cancer Res.
1:1017–1026. 2003.PubMed/NCBI
|
|
26
|
Tweddle DA, Pearson AD, Haber M, Norris
MD, Xue C, Flemming C and Lunec J: The p53 pathway and its
inactivation in neuroblastoma. Cancer Lett. 197:93–98. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Elias B, Laine A and Ronai Z:
Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear
export of Mdm2. Oncogene. 24:2574–2579. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanaka K: The proteasome: Overview of
structure and functions. Proc Jpn Acad Ser B Phys Biol Sci. 85:pp.
12–36. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bonvini P, Nguyen P, Trepel J and Neckers
LM: In vivo degradation of N-myc in neuroblastoma cells is mediated
by the 26S proteasome. Oncogene. 16:1131–1139. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kwak MK, Cho JM, Huang B, Shin S and
Kensler TW: Role of increased expression of the proteasome in the
protective effects of sulforaphane against hydrogen
peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free
Radic Biol Med. 43:809–817. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Laetsch T, Liu X, Vu A, Sliozberg M, Vido
M, Elci OU, Goldsmith KC and Hogarty MD: Multiple components of the
spliceosome regulate Mcl1 activity in neuroblastoma. Cell Death
Dis. 5:e10722014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goldsmith KC, Lestini BJ, Gross M, Ip L,
Bhumbla A, Zhang X, Zhao H, Liu X and Hogarty MD: BH3 response
profiles from neuroblastoma mitochondria predict activity of small
molecule Bcl-2 family antagonists. Cell Death Differ. 17:872–882.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goldsmith KC, Gross M, Peirce S, Luyindula
D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP and Hogarty
MD: Mitochondrial Bcl-2 family dynamics define therapy response and
resistance in neuroblastoma. Cancer Res. 72:2565–2577. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liang J, Parchaliuk D, Medina S, Sorensen
G, Landry L, Huang S, Wang M, Kong Q and Booth SA: Activation of
p53-regulated pro-apoptotic signaling pathways in PrP-mediated
myopathy. BMC Genomics. 10:2012009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Goga A, Yang D, Tward AD, Morgan DO and
Bishop JM: Inhibition of CDK1 as a potential therapy for tumors
over-expressing MYC. Nat Med. 13:820–827. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bettayeb K, Oumata N, Echalier A, Ferandin
Y, Endicott JA, Galons H and Meijer L: CR8, a potent and selective,
roscovitine-derived inhibitor of cyclin-dependent kinases.
Oncogene. 27:5797–5807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Y, Tsai YH and Tseng SH: Inhibition
of cyclin-dependent kinase 1-induced cell death in neuroblastoma
cells through the microRNA-34a-MYCN-survivin pathway. Surgery.
153:4–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Santamaría D, Barrière C, Cerqueira A,
Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M and
Barbacid M: Cdk1 is sufficient to drive the mammalian cell cycle.
Nature. 448:811–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tetsu O and McCormick F: Proliferation of
cancer cells despite CDK2 inhibition. Cancer Cell. 3:233–245. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Casellas P, Galiegue S and Basile AS:
Peripheral benzodiazepine receptors and mitochondrial function.
Neurochem Int. 40:475–486. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Santidrián AF, Cosialls AM, Coll-Mulet L,
Iglesias-Serret D, de Frias M, González-Gironès DM, Campàs C,
Domingo A, Pons G and Gil J: The potential anticancer agent PK11195
induces apoptosis irrespective of p53 and ATM status in chronic
lymphocytic leukemia cells. Haematologica. 92:1631–1638. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mendonça-Torres MC and Roberts SS: The
translocator protein (TSPO) ligand PK11195 induces apoptosis and
cell cycle arrest and sensitizes to chemotherapy treatment in pre-
and post-relapse neuroblastoma cell lines. Cancer Biol Ther.
14:319–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
